Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Demaree

Dermatology Eau Claire, WI Doctor of Osteopathy

NPI 1285164772 CMS profile 7231441

733 W Clairemont Ave, Eau Claire, WI 54701

Open in the dashboard

General payments

$736

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Demaree of Eau Claire, WI is reported in the CMS Open Payments database as having received $736 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $186 2
2022 General $50 3
2021 General $200 14
2020 General $158 8
2019 General $142 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Demaree
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Elizabeth Demaree were reported at $186. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Elizabeth Demaree Dermatology median Middle half National median
2019 $142 $454 $129–$1,240 $163
2020 $158 $235 $81–$756 $114
2021 $200 $377 $108–$1,108 $132
2022 $50 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $186 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $258 14 payments
  2. Regeneron Healthcare Solutions, Inc. $144 3 payments
  3. Galderma Laboratories, L.P. $138 2 payments
  4. Amgen Inc. $104 5 payments
  5. Helsinn Therapeutics (U.S.), Inc. $26 2 payments
  6. Novartis Pharmaceuticals Corporation $25 1 payment
  7. Lilly USA, LLC $18 1 payment
  8. Genentech USA, Inc. $13 1 payment
  9. Pfizer Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $736 30 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $144 3 payments
  2. NEMLUVIO $125 1 payment
  3. Otezla $104 5 payments
  4. RINVOQ $93 3 payments
  5. SKYRIZI $86 4 payments
  6. HUMIRA $75 7 payments
  7. VALCHLOR $26 2 payments
  8. COSENTYX $25 1 payment
  9. TALTZ $18 1 payment
  10. ORACEA $13 1 payment
  11. Other $39 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

653

Median for Dermatology: 534

Drug cost

$542,320

Median for Dermatology: $67,151

Branded share of claims

13.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 37 $439,406
Dupixent Pen Dupilumab Brand 22 $82,744
Ketoconazole Generic 231 $4,017
Metronidazole Generic 46 $3,861
Clobetasol Propionate Generic 89 $3,129
Fluorouracil Generic 30 $2,459
Tacrolimus Generic 17 $2,422
Calcipotriene Generic 12 $947
Ciclopirox Generic 28 $843
Fluocinonide Generic 22 $703

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$51,484

Medicare's payments for the services billed

Medicare patients

459

Average age 73

Services billed

1,396

268 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 37%
Chronic kidney disease 24%
Diabetes 19%
Depression 18%
Ischemic heart disease 17%
Osteoporosis 15%
Cancer 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record